NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.36 +0.37 (+1.68 %) (As of 05/23/2019 01:15 AM ET)Previous Close$21.99Today's Range$21.5456 - $22.659952-Week Range$18.20 - $38.78Volume49,992 shsAverage Volume64,473 shsMarket Capitalization$249.47 millionP/E Ratio52.00Dividend YieldN/ABeta1.7 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida. Receive IRMD News and Ratings via Email Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD Previous Symbol CUSIPN/A CIK1325618 Webhttp://www.iradimed.com/ Phone407-677-8022Debt Debt-to-Equity Ratio0.06 Current Ratio9.48 Quick Ratio8.63Price-To-Earnings Trailing P/E Ratio52.00 Forward P/E Ratio34.94 P/E GrowthN/A Sales & Book Value Annual Sales$30.44 million Price / Sales8.20 Cash Flow$0.5773 per share Price / Cash Flow38.73 Book Value$4.00 per share Price / Book5.59Profitability EPS (Most Recent Fiscal Year)$0.43 Net Income$6.30 million Net Margins23.00% Return on Equity13.98% Return on Assets11.82%Miscellaneous Employees95 Outstanding Shares11,157,000Market Cap$249.47 million Next Earnings Date7/30/2019 (Estimated) OptionableNot Optionable Iradimed (NASDAQ:IRMD) Frequently Asked Questions What is Iradimed's stock symbol? Iradimed trades on the NASDAQ under the ticker symbol "IRMD." How will Iradimed's stock buyback program work? Iradimed declared that its Board of Directors has authorized a stock buyback plan on Sunday, June 4th 2017, which allows the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's leadership believes its shares are undervalued. How were Iradimed's earnings last quarter? Iradimed Corp (NASDAQ:IRMD) announced its quarterly earnings data on Tuesday, April, 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, hitting the consensus estimate of $0.11. The medical equipment provider earned $8.44 million during the quarter, compared to analyst estimates of $8.38 million. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. View Iradimed's Earnings History. When is Iradimed's next earnings date? Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Iradimed. What guidance has Iradimed issued on next quarter's earnings? Iradimed updated its second quarter 2019 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of $0.14-0.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.17. The company issued revenue guidance of $8.8-9 million, compared to the consensus revenue estimate of $9.39 million.Iradimed also updated its FY 2019 guidance to $0.69-0.73 EPS. What price target have analysts set for IRMD? 1 brokerages have issued 1-year price objectives for Iradimed's stock. Their predictions range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price. View Analyst Price Targets for Iradimed. What is the consensus analysts' recommendation for Iradimed? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed. Has Iradimed been receiving favorable news coverage? News headlines about IRMD stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Iradimed earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the stock's share price in the immediate future. Who are some of Iradimed's key competitors? Some companies that are related to Iradimed include Luminex (LMNX), Tactile Systems Technology (TCMD), Axonics Modulation Technologies (AXNX), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), Orthopediatrics (KIDS), SurModics (SRDX), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), OraSure Technologies (OSUR), Antares Pharma (ATRS), SI-Bone (SIBN), GenMark Diagnostics (GNMK) and MiMedx Group (MDXG). What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), BioTelemetry (BEAT), Intuitive Surgical (ISRG), Paypal (PYPL), Palo Alto Networks (PANW), Alphabet (GOOG), IntriCon (IIN), Micron Technology (MU), GrubHub (GRUB) and ABIOMED (ABMD). Who are Iradimed's key executives? Iradimed's management team includes the folowing people: Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)Mr. Christopher K. Scott, CFO & Sec. (Age 49)Mr. John McCreery, Chief Operating Officer (Age 64)Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)Mr. Louis Waldman, Controller (Age 64) Who are Iradimed's major shareholders? Iradimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.10%), BlackRock Inc. (3.06%), Cadence Capital Management LLC (1.17%), RK Capital Management LLC (1.16%), Spark Investment Management LLC (0.50%) and Fiera Capital Corp (0.46%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed. Which major investors are selling Iradimed stock? IRMD stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Timpani Capital Management LLC, Morgan Stanley, O Shaughnessy Asset Management LLC and Federated Investors Inc. PA. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed. Which major investors are buying Iradimed stock? IRMD stock was acquired by a variety of institutional investors in the last quarter, including RK Capital Management LLC, Fiera Capital Corp, Cadence Capital Management LLC, Spark Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., Marshall Wace LLP and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Iradimed. How do I buy shares of Iradimed? Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Iradimed's stock price today? One share of IRMD stock can currently be purchased for approximately $22.36. How big of a company is Iradimed? Iradimed has a market capitalization of $249.47 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe. What is Iradimed's official website? The official website for Iradimed is http://www.iradimed.com/. How can I contact Iradimed? Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected] MarketBeat Community Rating for Iradimed (NASDAQ IRMD)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 198 (Vote Outperform)Underperform Votes: 203 (Vote Underperform)Total Votes: 401MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is a good rate of return for a mutual fund? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.